Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
Background and purpose: Several clinical trials have indicated that the use of canagliflozin increases the risk of lower extremity amputation. Although the US Food and Drug Administration (FDA) has withdrawn its black box warning about amputation risk for canagliflozin, the risk still exists. We sou...
Main Authors: | Hui Zhao, Zi-Ran Li, Qian Zhang, Ming-Kang Zhong, Ming-Ming Yan, Xiao-Yan Qiu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1110575/full |
Similar Items
-
Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
by: Hui Zhao, et al.
Published: (2023-07-01) -
Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database
by: Zhao Li, et al.
Published: (2024-03-01) -
Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
by: Junwei Wang, et al.
Published: (2024-03-01) -
Electrolyte Disorders Associated with Piperacillin/Tazobactam: A Pharmacovigilance Study Using the FAERS Database
by: Heenam Seo, et al.
Published: (2023-01-01) -
Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database
by: Yamin Shu, et al.
Published: (2022-09-01)